M Schaafsma

2.1k total citations
13 papers, 759 citations indexed

About

M Schaafsma is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, M Schaafsma has authored 13 papers receiving a total of 759 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 5 papers in Molecular Biology and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in M Schaafsma's work include Acute Myeloid Leukemia Research (4 papers), Acute Lymphoblastic Leukemia research (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). M Schaafsma is often cited by papers focused on Acute Myeloid Leukemia Research (4 papers), Acute Lymphoblastic Leukemia research (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). M Schaafsma collaborates with scholars based in Netherlands, Belgium and United States. M Schaafsma's co-authors include Pieter Sonneveld, Edo Vellenga, Harry C. Schouten, Bronno van der Holt, Marinus H. J. van Oers, Gert J. Ossenkoppele, Bob Löwenberg, Johan Maertens, Leo F. Verdonck and Jan J. Cornelissen and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

M Schaafsma

13 papers receiving 745 citations

Peers

M Schaafsma
Howard R. Terebelo United States
Jan Maxwell Nørgaard Denmark
S Kulkarni United Kingdom
Antònia Sampol Spain
David Szwajcer Canada
Sarah Bertoli France
Georgine E. de Greef Netherlands
E. Winton United States
P. C. Hoffman United States
C Skosey United States
Howard R. Terebelo United States
M Schaafsma
Citations per year, relative to M Schaafsma M Schaafsma (= 1×) peers Howard R. Terebelo

Countries citing papers authored by M Schaafsma

Since Specialization
Citations

This map shows the geographic impact of M Schaafsma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Schaafsma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Schaafsma more than expected).

Fields of papers citing papers by M Schaafsma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Schaafsma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Schaafsma. The network helps show where M Schaafsma may publish in the future.

Co-authorship network of co-authors of M Schaafsma

This figure shows the co-authorship network connecting the top 25 collaborators of M Schaafsma. A scholar is included among the top collaborators of M Schaafsma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Schaafsma. M Schaafsma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Minnema, Monique C., Kazem Nasserinejad, Bouke P. C. Hazenberg, et al.. (2019). Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica. 104(11). 2274–2282. 23 indexed citations
2.
Stevens‐Kroef, Marian, Daniël Olde Weghuis, Bert van der Reijden, et al.. (2017). Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial. Genes Chromosomes and Cancer. 56(7). 524–534. 13 indexed citations
3.
Bouman, Donald E., et al.. (2014). Hepatocellular carcinoma after danazol treatment for hereditary angio-oedema.. PubMed. 72(7). 380–2. 3 indexed citations
4.
Löwenberg, Bob, Thomas Pabst, Edo Vellenga, et al.. (2011). Cytarabine Dose for Acute Myeloid Leukemia. New England Journal of Medicine. 364(11). 1027–1036. 276 indexed citations
5.
Wijermans, P. W., Sonja Zweegman, Marinus van Marwijk Kooy, et al.. (2009). A116 MP versus MPT in Elderly Myeloma Patients: The Final Outcome of the HOVON-49 Study. Clinical Lymphoma & Myeloma. 9. S18–S19. 3 indexed citations
6.
7.
Holt, Bronno van der, Christine M. Segeren, Edo Vellenga, et al.. (2007). Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica. 92(7). 928–935. 57 indexed citations
8.
Doorduijn, Jeanette K., Bronno van der Holt, Gustaaf W. van Imhoff, et al.. (2003). CHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology. 21(16). 3041–3050. 132 indexed citations
9.
10.
Ossenkoppele, G. J., Wilfried J. Graveland, Pieter Sonneveld, et al.. (2002). Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood. 100(11). 2 indexed citations
11.
Ossenkoppele, GJ, Bronno van der Holt, Pieter Sonneveld, et al.. (2001). A randomized study on the value of Fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. A report from the Dutch-Belgian hemato-oncology cooperative group (HOVON). Blood. 98(11). 2 indexed citations
12.
Schaafsma, M, et al.. (1994). Lactic acidosis in a patient with B-cell non-Hodgkin's lymphoma.. PubMed. 8(6). 1065–6. 8 indexed citations
13.
Schaafsma, M, et al.. (1987). Staging and treatment of non‐Hodgkin's lymphoma of intermediate‐grade malignancy: A retrospectective study of 102 cases. European Journal Of Haematology. 39(3). 252–258. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Howard R. Terebelo Breakdown of academic impact, for papers by Jan Maxwell Nørgaard Breakdown of academic impact, for papers by S Kulkarni Breakdown of academic impact, for papers by Antònia Sampol Breakdown of academic impact, for papers by David Szwajcer Breakdown of academic impact, for papers by Sarah Bertoli Breakdown of academic impact, for papers by Georgine E. de Greef Breakdown of academic impact, for papers by E. Winton Breakdown of academic impact, for papers by P. C. Hoffman Breakdown of academic impact, for papers by C Skosey
Rankless by CCL
2026